Types of Research Grants

Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Types of Research Grants

Grants Overview Types of Grants Process and Timeline Funded Studies

The Alzheimer's Association funds a wide variety of investigations by scientists at every stage of their careers. Each grant is designed to meet the needs of the field and to introduce fresh ideas in Alzheimer's research.

Part the Cloud Request for Applications (RFA): Translational Research Funding for Alzheimer’s Disease – PCTR:
May – November 2015

Program Announcement (3 pages)

In its fourth iteration, the Alzheimer's Association is pleased to announce the Part the Cloud Translational Research Funding initiative to increase the research efforts in Phase I and Phase II (Proof of Concept) clinical trials directed towards Alzheimer’s disease and related dementias in North America.

There is no greater healthcare need than slowing or preventing Alzheimer’s disease. The vast increase in understanding of the neurobiology of AD in recent decades, from genetic factors to amyloid accumulation, tangle formation, cellular dysfunction and synaptic failure, has led to the identification of highly promising targets for new therapies. Among the therapeutic strategies being pursued are beta and gamma secretase inhibitors to reduce amyloid production, immune-therapeutics to increase clearance of amyloid, immune-therapeutics targeting tau pathology, and various approaches to protecting brain cells from neurodegeneration. However, the process of developing candidate therapies is long and complex leading to the failure of many drug development programs. The steps from target identification to the clinic includes high-throughput screening, lead optimization, establishing target engagement in vitro and in vivo, assuring central nervous system penetration, animal toxicology and finally the three phases of human testing. The full process takes many years and substantial resources, and typically involves different groups of investigators at different stages.

CLOSED: Biomarkers Across Neurodegenerative Diseases - BAND:
March – October 2015

Program Announcement (4 pages)

The Alzheimer’s Association, Alzheimer’s Research UK, The Michael J. Fox Foundation for Parkinson's Research and the Weston Brain Institute announce a global Request for Applications (RFA), Biomarkers Across Neurodegenerative Diseases (BAND). The main objective of BAND is to stimulate analyses across Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases to increase understanding of pathogenesis similarities and differences. Analyses from this program may support, for example, biomarker discovery, assay standardization, genetic profiling, harmonization of existing data set phenotypes, cross-disease analysis of existing genetic data, inclusion of other neurodegenerative diseases related to PD and AD, and imaging development.The RFA aims to build on existing momentum to leverage similar activities and increase impact across the neurodegenerative disease spectrum. It also builds on recent evidence suggesting substantial overlap between AD, PD, and other neurodegenerative diseases pathologically, but also, potentially, biologically.


CLOSED: Mechanisms of cellular death in NeuroDegeneration - MCDN: February – September 2015

Program Announcement (4 pages)

The Alzheimer’s Association, Alzheimer’s Research UK and the Weston Brain Institute announce a collaborative Request for Applications (RFA). The "Mechanisms of cellular death in NeuroDegeneration" (MCDN) funding program’s overall goal is to discover and understand the mechanisms and pathophysiological processes by which brain cell loss is medicated in disease and thereby seek insights and potential targets for therapeutic interventions that would sustain healthy brain function.

Application procedures and key dates are now available, visit for information regarding eligibility and requirements.


CLOSED: Collaboration 4 Cure- C4C:
March - June 2015

Program Announcement (4 pages)

The Alzheimer’s Association, in partnership with the Salk Institute (Salk), Sanford-Burnham Medical Research Institute (Sanford|Burnham), the Scripps Research Institute (Scripps), University of California, San Diego (UCSD), and the J. Craig Venter Institute (Venter), are launching the San Diego Dementia Drug Discovery Program – Collaboration 4 Cure (C4C), an innovate program to harvest the best research ideas toward effective therapy of Alzheimer’s disease and partner such projects with the translational drug discovery infrastructure at Sanford| Burnham and Scripps. The C4C program will provide services to investigators in the form of early drug discovery capabilities and is not a direct funding mechanism for individual investigator laboratories. Both non-profit and small for-profit agencies are eligible. The C4C program is open to any principal investigator holding a faculty appointment at any accredited, greater San Diego area-based University, academic institution, hospital, medical practice or not-for-profit medical or life sciences research institution, inclusive of stakeholder institutes: UCSD, Salk Institute, The Scripps Research Institute, the Venter Institute and Sanford-Burnham Medical Research Institute.


CLOSED: All Investigators Program: January 2015 - August 2015

2015 Complete All Investigators Program Announcement (71 pages)

Investigator-Initiated Research Grant – Request for Applications

a. Biological Underpinnings of Genetic Risk Factors in Alzheimer’s disease (BGF)

b. Discovery-Validation of Therapeutic Targets for Developing Novel Interventions of Alzheimer’s disease (DVT) -

c. Non-Pharmacological Strategies to Ameliorate Symptoms of Alzheimer’s Disease and Related Dementia (NPSASA)

d. Role of Vascular Metabolic Factors in Pathogenesis of Alzheimer’s disease and Related Dementia (VMF)

e. Understanding the Development and Devising Treatments for Alzheimer’s Disease in Individuals with Down Syndrome (DS/AD)

New Investigator Research Grant (NIRG) (3 pages)

New Investigator Research Grant to Promote Diversity (NIRGD)
(3 pages)

Mentored New Investigator Research Grant to Promote Diversity (MNIRGD) (4 pages)

The Zenith Fellows Award Program (ZENITH) (3 pages)

Everyday Technologies for Alzheimer Care (ETAC) (3 pages)


How to apply for a grant

See the Application Process and Timeline page for information about the grants application process, review procedures and reporting requirements.



For more information: Contact or call 312.335.5747.